Manali Kamdar, ASH 2021: Results from the Randomized Phase III TRANSFORM Study
We were delighted to catch up with Dr Manali Kamdar (University of Colorado, Boulder, CO, USA) to discuss the results of the randomized phase III TRANSFORM study of lisocabtagene maraleucel CAR-T cell therapy versus standard of care chemotherapy followed by ASCT in patients with relapsed or refractory large b-cell lymphoma.
Question
Please can you summarise the aims, design, eligibility criteria and efficacy and safety findings of the TRANSFORM study?
Speaker Disclosure: Manali Kamdar discloses research support/funding from TG Therapeutics, Genentech and Novartis; Consultancy to AbbVie, AstraZeneca, Celgene/Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics and Beigene; speaker’s bureau to SeaGen and DMC to Celgene and Genentech.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition